TUSTIN, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, towards commercialization and providing integrated cGMP clinical and commercial bio-manufacturing services, announced that Steven W. King, president and chief executive officer, will present a company update at the 27th Annual ROTH Conference on Monday, March 9th, 2015 at 10:00 AM Pacific Time (1:00 PM Eastern Time) at The Ritz-Carlton Laguna Niguel in Dana Point, California.
Peregrine's presentation at the ROTH conference will be webcast live and available for replay for 30 days at: http://ir.peregrineinc.com/events.cfm
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immuno-oncology candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
CONTACT: Christopher Keenan Peregrine Pharmaceuticals, Inc. (800) 987-8256 firstname.lastname@example.org
Source:Peregrine Pharmaceuticals, Inc.